Bragar Eagel & Squire Investigates Potential Claims Against Qiagen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 33 minutes ago
0mins
Should l Buy QGEN?
Source: Globenewswire
- Legal Investigation Launched: Bragar Eagel & Squire is investigating whether Qiagen has violated federal securities laws, which could impact investor confidence and the company's reputation.
- Declining Financial Performance: Qiagen's Q1 2026 report indicated a 1% decline in net sales on a constant exchange rate basis, with QuantiFERON product sales down approximately 5%, raising concerns about future performance among investors.
- Stock Price Volatility: Following the financial report on April 27, 2026, Qiagen's stock price fell from $38.09 to $34.02, a drop of about 11%, reflecting negative market sentiment regarding the company's financial health.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to reach out to discuss legal options, demonstrating the firm's commitment to safeguarding shareholder rights and potentially leading to further legal actions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QGEN
Wall Street analysts forecast QGEN stock price to rise
14 Analyst Rating
8 Buy
6 Hold
0 Sell
Moderate Buy
Current: 33.290
Low
45.00
Averages
50.57
High
55.00
Current: 33.290
Low
45.00
Averages
50.57
High
55.00
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Qiagen Lowers FY 2026 Sales Growth Guidance
- Sales Growth Guidance Cut: Qiagen has reduced its FY 2026 sales growth forecast from at least 5% to just 1-2%, resulting in approximately a 10% loss in shareholder investment value, indicating weakened market demand.
- Earnings Per Share Downgrade: The adjusted diluted EPS guidance has been lowered from ≥$2.50 to ≥$2.43, reflecting a decline in the company's profitability, which may impact investor confidence and lead to further stock price volatility.
- Executive Accountability: CEO Thierry Bernard and CFO Roland Sackers were directly responsible for public communications during the investigation period, and their failure to meet promised sales targets could trigger a crisis of trust among shareholders.
- Legal Consultation Opportunity: Affected investors are encouraged to contact Levi & Korsinsky to discuss potential legal rights, highlighting market concerns regarding corporate governance and transparency.
See More
Bragar Eagel & Squire Investigates Potential Claims Against Qiagen
- Legal Investigation Launched: Bragar Eagel & Squire is investigating whether Qiagen has violated federal securities laws, which could impact investor confidence and the company's reputation.
- Declining Financial Performance: Qiagen's Q1 2026 report indicated a 1% decline in net sales on a constant exchange rate basis, with QuantiFERON product sales down approximately 5%, raising concerns about future performance among investors.
- Stock Price Volatility: Following the financial report on April 27, 2026, Qiagen's stock price fell from $38.09 to $34.02, a drop of about 11%, reflecting negative market sentiment regarding the company's financial health.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to reach out to discuss legal options, demonstrating the firm's commitment to safeguarding shareholder rights and potentially leading to further legal actions.
See More
Qiagen Under Investigation for Securities Fraud Claims
- Sales Performance Decline: Qiagen's preliminary results for Q1 2026 revealed a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales dropping about 5%, indicating pressure in market competition that could hinder future revenue growth.
- Significant Stock Drop: Following the sales decline announcement, Qiagen's stock price fell by $4.07, or 10.69%, closing at $34.02 per share on April 28, 2026, which may raise investor concerns regarding the company's financial health.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Qiagen and certain officers or directors engaged in securities fraud or other unlawful business practices, which could lead to legal liabilities and potential damages, further impacting the company's market reputation.
- Increased Investor Attention: As the investigation unfolds, investors are advised to contact Pomerantz LLP, indicating a rising market focus on Qiagen that may affect shareholder confidence and future investment decisions.
See More
Qiagen Under Investigation for Possible Securities Violations
- Earnings Warning: Qiagen's preliminary results for Q1 2026 indicate a 1% decline in net sales on a constant exchange rate basis, with QuantiFERON sales down approximately 5%, suggesting significant sales pressure that could impact future profitability.
- Stock Price Volatility: Following the sales decline announcement, Qiagen's stock price fell by $4.07, or about 11%, from $38.09 to $34.02 on April 28, 2026, reflecting market concerns regarding the company's performance.
- Legal Investigation Initiated: Kirby McInerney LLP has reminded investors of an ongoing investigation into possible violations of federal securities laws by Qiagen and its senior management, with no lawsuits filed yet, which may affect investor confidence.
- Investor Action Recommendation: The law firm encourages investors who purchased or acquired Qiagen securities to contact them to discuss their rights, indicating that the potential legal issues could have significant implications for shareholders.
See More
QIAGEN Nominates New Board Member and Proposes Dividend Increase
- Board Renewal: QIAGEN has nominated Robert McMahon for election to the Supervisory Board as part of an ongoing renewal process, with seven of the eight proposed members having joined since 2021, ensuring continuity and governance efficiency.
- Dividend Increase: The company proposes a 40% increase in its annual cash dividend to $0.35 per share, reflecting a continued commitment to shareholder returns while maintaining flexibility for long-term growth investments.
- Share Repurchase Plan: QIAGEN seeks shareholder approval for additional share repurchase authorizations, including up to $200 million in synthetic share repurchases, aimed at enhancing capital allocation flexibility and boosting shareholder returns.
- Management Stability: Current CEO Thierry Bernard will continue to serve as a Managing Board member until a new CEO is appointed, ensuring leadership stability and strategic execution during the transition period.
See More
Schall Law Firm Investigates Qiagen for Securities Violations
- Investigation Launched: The Schall Law Firm has initiated an investigation into Qiagen N.V. regarding potential violations of securities laws, focusing on whether the company issued false or misleading statements that could harm investors' interests, highlighting serious concerns about corporate transparency.
- Diverging Performance Expectations: Qiagen initially projected a 6% to 7% growth for QuantiFERON during its February 2026 earnings call, but the CFO's April 28 disclosure indicated sales would remain largely unchanged from Q2 2025, reflecting a significant downward revision in company performance expectations.
- Investor Losses: As the company fails to meet growth expectations, investors may incur losses, prompting the Schall Law Firm to encourage affected shareholders to participate in the investigation to protect their legal rights, underscoring the importance of legal recourse in such situations.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations to assist investors in understanding their rights and taking necessary legal actions, emphasizing the need for investor protection in the securities market.
See More
Qiagen Lowers FY 2026 Sales Growth Guidance
- Sales Growth Guidance Cut: Qiagen has reduced its FY 2026 sales growth forecast from at least 5% to just 1-2%, resulting in approximately a 10% loss in shareholder investment value, indicating weakened market demand.
- Earnings Per Share Downgrade: The adjusted diluted EPS guidance has been lowered from ≥$2.50 to ≥$2.43, reflecting a decline in the company's profitability, which may impact investor confidence and lead to further stock price volatility.
- Executive Accountability: CEO Thierry Bernard and CFO Roland Sackers were directly responsible for public communications during the investigation period, and their failure to meet promised sales targets could trigger a crisis of trust among shareholders.
- Legal Consultation Opportunity: Affected investors are encouraged to contact Levi & Korsinsky to discuss potential legal rights, highlighting market concerns regarding corporate governance and transparency.
See More
Bragar Eagel & Squire Investigates Potential Claims Against Qiagen
- Legal Investigation Launched: Bragar Eagel & Squire is investigating whether Qiagen has violated federal securities laws, which could impact investor confidence and the company's reputation.
- Declining Financial Performance: Qiagen's Q1 2026 report indicated a 1% decline in net sales on a constant exchange rate basis, with QuantiFERON product sales down approximately 5%, raising concerns about future performance among investors.
- Stock Price Volatility: Following the financial report on April 27, 2026, Qiagen's stock price fell from $38.09 to $34.02, a drop of about 11%, reflecting negative market sentiment regarding the company's financial health.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to reach out to discuss legal options, demonstrating the firm's commitment to safeguarding shareholder rights and potentially leading to further legal actions.
See More
Qiagen Under Investigation for Securities Fraud Claims
- Sales Performance Decline: Qiagen's preliminary results for Q1 2026 revealed a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales dropping about 5%, indicating pressure in market competition that could hinder future revenue growth.
- Significant Stock Drop: Following the sales decline announcement, Qiagen's stock price fell by $4.07, or 10.69%, closing at $34.02 per share on April 28, 2026, which may raise investor concerns regarding the company's financial health.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Qiagen and certain officers or directors engaged in securities fraud or other unlawful business practices, which could lead to legal liabilities and potential damages, further impacting the company's market reputation.
- Increased Investor Attention: As the investigation unfolds, investors are advised to contact Pomerantz LLP, indicating a rising market focus on Qiagen that may affect shareholder confidence and future investment decisions.
See More
Qiagen Under Investigation for Possible Securities Violations
- Earnings Warning: Qiagen's preliminary results for Q1 2026 indicate a 1% decline in net sales on a constant exchange rate basis, with QuantiFERON sales down approximately 5%, suggesting significant sales pressure that could impact future profitability.
- Stock Price Volatility: Following the sales decline announcement, Qiagen's stock price fell by $4.07, or about 11%, from $38.09 to $34.02 on April 28, 2026, reflecting market concerns regarding the company's performance.
- Legal Investigation Initiated: Kirby McInerney LLP has reminded investors of an ongoing investigation into possible violations of federal securities laws by Qiagen and its senior management, with no lawsuits filed yet, which may affect investor confidence.
- Investor Action Recommendation: The law firm encourages investors who purchased or acquired Qiagen securities to contact them to discuss their rights, indicating that the potential legal issues could have significant implications for shareholders.
See More
QIAGEN Nominates New Board Member and Proposes Dividend Increase
- Board Renewal: QIAGEN has nominated Robert McMahon for election to the Supervisory Board as part of an ongoing renewal process, with seven of the eight proposed members having joined since 2021, ensuring continuity and governance efficiency.
- Dividend Increase: The company proposes a 40% increase in its annual cash dividend to $0.35 per share, reflecting a continued commitment to shareholder returns while maintaining flexibility for long-term growth investments.
- Share Repurchase Plan: QIAGEN seeks shareholder approval for additional share repurchase authorizations, including up to $200 million in synthetic share repurchases, aimed at enhancing capital allocation flexibility and boosting shareholder returns.
- Management Stability: Current CEO Thierry Bernard will continue to serve as a Managing Board member until a new CEO is appointed, ensuring leadership stability and strategic execution during the transition period.
See More
Schall Law Firm Investigates Qiagen for Securities Violations
- Investigation Launched: The Schall Law Firm has initiated an investigation into Qiagen N.V. regarding potential violations of securities laws, focusing on whether the company issued false or misleading statements that could harm investors' interests, highlighting serious concerns about corporate transparency.
- Diverging Performance Expectations: Qiagen initially projected a 6% to 7% growth for QuantiFERON during its February 2026 earnings call, but the CFO's April 28 disclosure indicated sales would remain largely unchanged from Q2 2025, reflecting a significant downward revision in company performance expectations.
- Investor Losses: As the company fails to meet growth expectations, investors may incur losses, prompting the Schall Law Firm to encourage affected shareholders to participate in the investigation to protect their legal rights, underscoring the importance of legal recourse in such situations.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations to assist investors in understanding their rights and taking necessary legal actions, emphasizing the need for investor protection in the securities market.
See More
